Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ MNAR Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA563893
Description
Immunogen sequence: GPPTTANHLG LSVPGLVSVP PRLLPGPENH RAGSNEDPIL APSGTPPPTI PPDETFGGRV PRPAFVHYDK EEASDVEISL ESDSDDSVVI VPE Highest antigen sequence identity to the following orthologs: Mouse - 96%, Rat - 94%.
This gene encodes a transcription factor which coactivates transcription of estrogen receptor responsive genes and corepresses genes activated by other hormone receptors or sequence-specific transcription factors. Expression of this gene is regulated by both members of the estrogen receptor family. This gene may be involved in the progression of several types of cancer. Alternative splicing results in multiple transcript variants.
Specifications
MNAR | |
Polyclonal | |
Unconjugated | |
PELP1 | |
4930563C04Rik; HMX3; Mnar; modulator of nongenomic activity of estrogen receptor; Modulator of non-genomic activity of estrogen receptor; P160; PELP1; proline and glutamic acid rich nuclear protein; proline, glutamate and leucine rich protein 1; proline, glutamic acid and leucine rich protein 1; proline-, glutamic acid- and leucine-rich protein 1; proline-, glutamic acid-, leucine-rich protein 1; RGD1306320; transcription factor HMX3 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
27043 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Immunohistochemistry (Paraffin) | |
0.05 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q8IZL8 | |
PELP1 | |
Recombinant protein corresponding to Human MNAR. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction